Claudia Fabiani1, Jurgen Sota2, Antonio Vitale2, Giacomo Emmi3, Lorenzo Vannozzi4, Daniela Bacherini4, Giuseppe Lopalco5, Silvana Guerriero6, Vincenzo Venerito5, Ida Orlando2, Rossella Franceschini7, Fiorella Fusco7, Bruno Frediani2, Mauro Galeazzi2, Florenzo Iannone5, Gian Marco Tosi7, Luca Cantarini2. 1. a Department of Ophthalmology , Humanitas Clinical and Research Center , Rozzano (Milan) , Italy. 2. b Research Center of Systemic Autoinflammatory Diseases and Behçet's Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences , University of Siena , Siena , Italy. 3. c Department of Experimental and Clinical Medicine , University of Florence , Florence , Italy. 4. d Department of Surgery and Translational Medicine, Eye Clinic , University of Florence , Florence , Italy . 5. e Interdisciplinary Department of Medicine, Rheumatology Unit , University of Bari , Bari , Italy. 6. f Department of Ophthalmology and Otolaryngology , University of Bari , Bari , Italy. 7. g Ophthalmology and Neurosurgery Department , University of Siena , Siena , Italy.
Abstract
PURPOSE: To evaluate the 10-year drug retention rate of infliximab (IFX) in Behçet's disease (BD)-related uveitis, the effect of a concomitant use of disease modifying anti-rheumatic drugs (DMARDs) on drug survival and differences according to the lines of biologic treatment. METHODS: Cumulative survival rates were studied using the Kaplan-Meier plot, while the Log-rank (Mantel-Cox) test was used to compare survival curves. RESULTS: Forty patients (70 eyes) were eligible for analysis. The drug retention rates at 12-, 24-, 60- and 120-month follow-up were 89.03%, 86.16%, 75.66% and 47.11% respectively. No differences were identified according to the use of concomitant DMARDs (p = 0.20), while a statistically significant difference was observed in relation to the different lines of IFX treatment (p = 0.014). Visual acuity improved from baseline to the last follow-up visit (p = 0.047) and a corticosteroid-sparing effect was observed (p < 0.0001). CONCLUSIONS: IFX retention rate in BD-uveitis is excellent and is not affected by concomitant DMARDs.
PURPOSE: To evaluate the 10-year drug retention rate of infliximab (IFX) in Behçet's disease (BD)-related uveitis, the effect of a concomitant use of disease modifying anti-rheumatic drugs (DMARDs) on drug survival and differences according to the lines of biologic treatment. METHODS: Cumulative survival rates were studied using the Kaplan-Meier plot, while the Log-rank (Mantel-Cox) test was used to compare survival curves. RESULTS: Forty patients (70 eyes) were eligible for analysis. The drug retention rates at 12-, 24-, 60- and 120-month follow-up were 89.03%, 86.16%, 75.66% and 47.11% respectively. No differences were identified according to the use of concomitant DMARDs (p = 0.20), while a statistically significant difference was observed in relation to the different lines of IFX treatment (p = 0.014). Visual acuity improved from baseline to the last follow-up visit (p = 0.047) and a corticosteroid-sparing effect was observed (p < 0.0001). CONCLUSIONS:IFX retention rate in BD-uveitis is excellent and is not affected by concomitant DMARDs.
Entities:
Keywords:
Behçet’s disease; drug retention rate; infliximab; treatment; uveitis
Authors: Claudia Fabiani; Antonio Vitale; Donato Rigante; Giacomo Emmi; Giuseppe Lopalco; Jurgen Sota; Lorenzo Vannozzi; Gerardo di Scala; Silvana Guerriero; Ida Orlando; Rossella Franceschini; Marco Capozzoli; Bruno Frediani; Mauro Galeazzi; Florenzo Iannone; Gian Marco Tosi; Luca Cantarini Journal: Clin Rheumatol Date: 2018-04-18 Impact factor: 2.980
Authors: Alejandro Gómez-Gómez; Alfredo Madrid-Garcia; Lara Borrego-Sanz; Paula Álvarez-Hernández; Pedro Arriola-Villalobos; Inés Pérez-Sancristobal; José M Benítez Del Castillo; Rosalía Mendez-Fernandez; Esperanza Pato-Cour; David Díaz-Valle; Luis Rodriguez-Rodriguez Journal: Ophthalmol Ther Date: 2022-10-20
Authors: Claudia Fabiani; Antonio Vitale; Giacomo Emmi; Alice Bitossi; Giuseppe Lopalco; Jurgen Sota; Silvana Guerriero; Ida Orlando; Marco Capozzoli; Fiorella Fusco; Francesco Rana; Florenzo Iannone; Bruno Frediani; Mauro Galeazzi; Lorenzo Vannozzi; Gian Marco Tosi; Luca Cantarini Journal: Clin Rheumatol Date: 2018-04-03 Impact factor: 2.980
Authors: Claudia Fabiani; Antonio Vitale; Giacomo Emmi; Arianna Sgheri; Giuseppe Lopalco; Jurgen Sota; Silvana Guerriero; Florenzo Iannone; Bruno Frediani; Lorenzo Vannozzi; Maria Teresa Bianco; Valtere Giovannini; Gian Marco Tosi; Luca Cantarini Journal: Front Pharmacol Date: 2019-12-09 Impact factor: 5.810